For instance, cytokines fused with antibodies against tumor markers like CD20 (66), programmed death protein 1 (67), and extra-domain B (EDB) of fibronectin (68) have shown promising results in cancer therapies and are currently being tested in clinical trials. This evidence concerns the gene FN1 and neoplasm.